Review



primary human umbilical vascular endothelial cells (huvecs)  (Cedarlane)


Bioz Verified Symbol Cedarlane is a verified supplier
Bioz Manufacturer Symbol Cedarlane manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cedarlane primary human umbilical vascular endothelial cells (huvecs)
    Primary Human Umbilical Vascular Endothelial Cells (Huvecs), supplied by Cedarlane, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+human+umbilical+vascular+endothelial+cells+(huvecs)/huvecs/pm40465229-50-0-10
    Average 90 stars, based on 1 article reviews
    primary human umbilical vascular endothelial cells (huvecs) - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Late-stage placental barrier model for transport studies of prescription drugs during pregnancy.
    Article Snippet: Primary human umbilical vascular endothelial cells (HUVECs) were purchased from CedarLane Labs (CAP0001GFP) and expanded in endothelial cell growth medium 2 (ECGM2, Sigma-Aldrich, C22011) supplemented with 1% antibiotic/antimycotic (100x, Sigma-Aldrich, A5955-100ML), on flasks coated with 0.2% gelatin, until passage 5.



    Similar Products

    umbilical vascular endothelial cells huvecs  (ATCC)
    99
    ATCC umbilical vascular endothelial cells huvecs
    Umbilical Vascular Endothelial Cells Huvecs, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+human+umbilical+vascular+endothelial+cells+(huvecs)/Primary+Umbilical+Vein+Endothelial+Cells%3B+Normal%2C+Human/pm41108330-41-23-28
    Average 99 stars, based on 1 article reviews
    umbilical vascular endothelial cells huvecs - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    primary human umbilical vascular endothelial cells (huvecs)  (Cedarlane)
    90
    Cedarlane primary human umbilical vascular endothelial cells (huvecs)
    Primary Human Umbilical Vascular Endothelial Cells (Huvecs), supplied by Cedarlane, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+human+umbilical+vascular+endothelial+cells+(huvecs)/huvecs/pm40465229-50-0-10
    Average 90 stars, based on 1 article reviews
    primary human umbilical vascular endothelial cells (huvecs) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    vascular endothelial cells huvecs primary umbilical vein endothelial cells  (ATCC)
    99
    ATCC vascular endothelial cells huvecs primary umbilical vein endothelial cells
    Vascular Endothelial Cells Huvecs Primary Umbilical Vein Endothelial Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+human+umbilical+vascular+endothelial+cells+(huvecs)/Primary+Umbilical+Vein+Endothelial+Cells%3B+Normal%2C+Human/pm40399348-152-3-15
    Average 99 stars, based on 1 article reviews
    vascular endothelial cells huvecs primary umbilical vein endothelial cells - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    normal primary human vascular endothelial cells huvec  (ATCC)
    99
    ATCC normal primary human vascular endothelial cells huvec
    rhMG53 inhibits vascular <t>endothelial</t> cell migration and tube formation. ( A ) rhMG53 did not induce cellular toxicity in <t>HUVEC</t> up to 100 μg/mL ( n = 5; ** p = 0.01). ( B ) Representative photomicrographs 24 h after scratch wounding, HUVEC treated with 50 μg/mL rhMG53 had significantly less migration and proliferation compared to control ( n = 9). Magnification 4×. ( C ) Quantification of the scratch area remaining at 24 h (**** p < 0.0001). ( D ) Representative photomicrographs and quantification of tube formation when HUVEC was seeded on Matrigel, followed by treatment with VEGF (10 ng/mL) with or without rhMG53 (50 μg/mL) for 18 h. rhMG53 significantly reduced tube length in VEGF-treated HUVEC ( n = 4; ** p = 0.0029). Magnification 4×. ( E ) HUVEC treated with IL-1B (10 ng/mL) with or without rhMG53 have decreased pSTAT3 protein expression; when normalized to total STAT3 expression, rhMG53 significantly (** p = 0.0084) decreased pSTAT3 ( n = 4). Statistical significance was assessed with the Kruskal–Wallis nonparametric test.
    Normal Primary Human Vascular Endothelial Cells Huvec, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+human+umbilical+vascular+endothelial+cells+(huvecs)/Primary+Umbilical+Vein+Endothelial+Cells%3B+Normal%2C+Human/pmc12030682-113-0-10
    Average 99 stars, based on 1 article reviews
    normal primary human vascular endothelial cells huvec - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    human umbilical vascular endothelial cells huvecs  (ATCC)
    99
    ATCC human umbilical vascular endothelial cells huvecs
    rhMG53 inhibits vascular <t>endothelial</t> cell migration and tube formation. ( A ) rhMG53 did not induce cellular toxicity in <t>HUVEC</t> up to 100 μg/mL ( n = 5; ** p = 0.01). ( B ) Representative photomicrographs 24 h after scratch wounding, HUVEC treated with 50 μg/mL rhMG53 had significantly less migration and proliferation compared to control ( n = 9). Magnification 4×. ( C ) Quantification of the scratch area remaining at 24 h (**** p < 0.0001). ( D ) Representative photomicrographs and quantification of tube formation when HUVEC was seeded on Matrigel, followed by treatment with VEGF (10 ng/mL) with or without rhMG53 (50 μg/mL) for 18 h. rhMG53 significantly reduced tube length in VEGF-treated HUVEC ( n = 4; ** p = 0.0029). Magnification 4×. ( E ) HUVEC treated with IL-1B (10 ng/mL) with or without rhMG53 have decreased pSTAT3 protein expression; when normalized to total STAT3 expression, rhMG53 significantly (** p = 0.0084) decreased pSTAT3 ( n = 4). Statistical significance was assessed with the Kruskal–Wallis nonparametric test.
    Human Umbilical Vascular Endothelial Cells Huvecs, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+human+umbilical+vascular+endothelial+cells+(huvecs)/Primary+Umbilical+Vein+Endothelial+Cells%3B+Normal%2C+Human%2C+Pooled/pmc11856147-64-0-11
    Average 99 stars, based on 1 article reviews
    human umbilical vascular endothelial cells huvecs - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    primary human umbilical vascular endothelial cells (huvecs; cc-2517)  (Lonza)
    90
    Lonza primary human umbilical vascular endothelial cells (huvecs; cc-2517)
    rhMG53 inhibits vascular <t>endothelial</t> cell migration and tube formation. ( A ) rhMG53 did not induce cellular toxicity in <t>HUVEC</t> up to 100 μg/mL ( n = 5; ** p = 0.01). ( B ) Representative photomicrographs 24 h after scratch wounding, HUVEC treated with 50 μg/mL rhMG53 had significantly less migration and proliferation compared to control ( n = 9). Magnification 4×. ( C ) Quantification of the scratch area remaining at 24 h (**** p < 0.0001). ( D ) Representative photomicrographs and quantification of tube formation when HUVEC was seeded on Matrigel, followed by treatment with VEGF (10 ng/mL) with or without rhMG53 (50 μg/mL) for 18 h. rhMG53 significantly reduced tube length in VEGF-treated HUVEC ( n = 4; ** p = 0.0029). Magnification 4×. ( E ) HUVEC treated with IL-1B (10 ng/mL) with or without rhMG53 have decreased pSTAT3 protein expression; when normalized to total STAT3 expression, rhMG53 significantly (** p = 0.0084) decreased pSTAT3 ( n = 4). Statistical significance was assessed with the Kruskal–Wallis nonparametric test.
    Primary Human Umbilical Vascular Endothelial Cells (Huvecs; Cc 2517), supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+human+umbilical+vascular+endothelial+cells+(huvecs)/huvecs+lonza/pmc11537455-95-0-8
    Average 90 stars, based on 1 article reviews
    primary human umbilical vascular endothelial cells (huvecs; cc-2517) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    primary human vascular umbilical vein endothelial cells  (Cell Applications Inc)
    95
    Cell Applications Inc primary human vascular umbilical vein endothelial cells
    rhMG53 inhibits vascular <t>endothelial</t> cell migration and tube formation. ( A ) rhMG53 did not induce cellular toxicity in <t>HUVEC</t> up to 100 μg/mL ( n = 5; ** p = 0.01). ( B ) Representative photomicrographs 24 h after scratch wounding, HUVEC treated with 50 μg/mL rhMG53 had significantly less migration and proliferation compared to control ( n = 9). Magnification 4×. ( C ) Quantification of the scratch area remaining at 24 h (**** p < 0.0001). ( D ) Representative photomicrographs and quantification of tube formation when HUVEC was seeded on Matrigel, followed by treatment with VEGF (10 ng/mL) with or without rhMG53 (50 μg/mL) for 18 h. rhMG53 significantly reduced tube length in VEGF-treated HUVEC ( n = 4; ** p = 0.0029). Magnification 4×. ( E ) HUVEC treated with IL-1B (10 ng/mL) with or without rhMG53 have decreased pSTAT3 protein expression; when normalized to total STAT3 expression, rhMG53 significantly (** p = 0.0084) decreased pSTAT3 ( n = 4). Statistical significance was assessed with the Kruskal–Wallis nonparametric test.
    Primary Human Vascular Umbilical Vein Endothelial Cells, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+human+umbilical+vascular+endothelial+cells+(huvecs)/Human+Umbilical+Vein+Endothelial+Cells%3A+HUVEC/bio_rxiv__2024__10__17__618860-243-0-8
    Average 95 stars, based on 1 article reviews
    primary human vascular umbilical vein endothelial cells - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    rhMG53 inhibits vascular endothelial cell migration and tube formation. ( A ) rhMG53 did not induce cellular toxicity in HUVEC up to 100 μg/mL ( n = 5; ** p = 0.01). ( B ) Representative photomicrographs 24 h after scratch wounding, HUVEC treated with 50 μg/mL rhMG53 had significantly less migration and proliferation compared to control ( n = 9). Magnification 4×. ( C ) Quantification of the scratch area remaining at 24 h (**** p < 0.0001). ( D ) Representative photomicrographs and quantification of tube formation when HUVEC was seeded on Matrigel, followed by treatment with VEGF (10 ng/mL) with or without rhMG53 (50 μg/mL) for 18 h. rhMG53 significantly reduced tube length in VEGF-treated HUVEC ( n = 4; ** p = 0.0029). Magnification 4×. ( E ) HUVEC treated with IL-1B (10 ng/mL) with or without rhMG53 have decreased pSTAT3 protein expression; when normalized to total STAT3 expression, rhMG53 significantly (** p = 0.0084) decreased pSTAT3 ( n = 4). Statistical significance was assessed with the Kruskal–Wallis nonparametric test.

    Journal: Pharmaceutics

    Article Title: Development of an Ophthalmic Hydrogel to Deliver MG53 and Promote Corneal Wound Healing †

    doi: 10.3390/pharmaceutics17040526

    Figure Lengend Snippet: rhMG53 inhibits vascular endothelial cell migration and tube formation. ( A ) rhMG53 did not induce cellular toxicity in HUVEC up to 100 μg/mL ( n = 5; ** p = 0.01). ( B ) Representative photomicrographs 24 h after scratch wounding, HUVEC treated with 50 μg/mL rhMG53 had significantly less migration and proliferation compared to control ( n = 9). Magnification 4×. ( C ) Quantification of the scratch area remaining at 24 h (**** p < 0.0001). ( D ) Representative photomicrographs and quantification of tube formation when HUVEC was seeded on Matrigel, followed by treatment with VEGF (10 ng/mL) with or without rhMG53 (50 μg/mL) for 18 h. rhMG53 significantly reduced tube length in VEGF-treated HUVEC ( n = 4; ** p = 0.0029). Magnification 4×. ( E ) HUVEC treated with IL-1B (10 ng/mL) with or without rhMG53 have decreased pSTAT3 protein expression; when normalized to total STAT3 expression, rhMG53 significantly (** p = 0.0084) decreased pSTAT3 ( n = 4). Statistical significance was assessed with the Kruskal–Wallis nonparametric test.

    Article Snippet: Normal primary human vascular endothelial cells (HUVEC) were purchased from ATCC (Manassas, VA, USA) and grown in F-12K medium containing endothelial cell growth supplement.

    Techniques: Migration, Control, Expressing